Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

ABIOMED stock price, quote, forecast and news

ABMD
US0036541003
873886

Price

0
Today +/-
-0
Today %
-0 %
P

ABIOMED stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the ABIOMED stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the ABIOMED stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the ABIOMED stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze ABIOMED's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

ABIOMED Stock Price History

DateABIOMED Price
12/23/20220 undefined
12/22/20220 undefined

ABIOMED Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into ABIOMED, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by ABIOMED from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects ABIOMED’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of ABIOMED. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into ABIOMED’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing ABIOMED’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on ABIOMED’s growth potential.

ABIOMED Revenue, EBIT and net profit per share

DateABIOMED RevenueABIOMED EBITABIOMED Net Income
2027e0 undefined0 undefined0 undefined
2026e0 undefined0 undefined0 undefined
2025e0 undefined0 undefined0 undefined
2024e0 undefined0 undefined0 undefined
2023e0 undefined0 undefined0 undefined
20220 undefined0 undefined0 undefined
20210 undefined0 undefined0 undefined
20200 undefined0 undefined0 undefined
20190 undefined0 undefined0 undefined
20180 undefined0 undefined0 undefined
20170 undefined0 undefined0 undefined
20160 undefined0 undefined0 undefined
20150 undefined0 undefined0 undefined
20140 undefined0 undefined0 undefined
20130 undefined0 undefined0 undefined
20120 undefined0 undefined0 undefined
20110 undefined0 undefined0 undefined
20100 undefined0 undefined0 undefined
20090 undefined0 undefined0 undefined
20080 undefined0 undefined0 undefined
20070 undefined0 undefined0 undefined
20060 undefined0 undefined0 undefined
20050 undefined0 undefined0 undefined
20040 undefined0 undefined0 undefined
20030 undefined0 undefined0 undefined

ABIOMED Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
19861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023e2024e2025e2026e2027e
000000000.010.010.010.020.020.020.020.020.030.020.030.040.040.050.060.070.090.10.130.160.180.230.330.450.590.770.840.851.031.161.341.541.711.81
-33.33--50.0050.00-33.33-50.00100.0033.3337.5036.3646.67-4.55-4.3522.73-14.818.7052.0013.1616.2816.0025.8616.4418.8224.7525.4015.8225.6843.0435.2633.2629.689.230.8321.7212.3215.7214.9311.105.79
100.00100.0075.0050.0033.33--33.3366.6762.5072.7366.6768.1868.1873.9168.1870.3765.2272.0073.6874.4276.0074.1471.2374.1278.2280.1679.7579.7882.6184.8084.0483.4783.0982.0280.8781.77-----
3431100145810151517151915182832384352637910112614619027937449563968968584300000
00-1-3-3-5-6-4-2000-2-7-11-25-24-19-10-3-17-27-35-29-25-111168286590157224249229256271333408470510
---25.00-150.00-100.00-250.00-300.00-133.33-33.33----9.09-31.82-47.83-113.64-88.89-82.61-40.00-7.89-39.53-54.00-60.34-39.73-29.41-10.890.7910.134.3712.1719.7620.2226.4829.1329.6427.0424.8323.4024.8526.4927.4728.18
000-2-1-6-5-3-2000-2-6-10-19-21-18-9-2-29-27-40-31-19-1111571133852112259203225136221256315367440
-----50.00500.00-16.67-40.00-33.33----200.0066.6790.0010.53-14.29-50.00-77.781,350.00-6.9048.15-22.50-38.71-42.11-109.091,400.00-53.331,514.29-66.3736.84115.38131.25-21.6210.84-39.5662.5015.8423.0516.5119.89
7.27.38.59.410.812.312.812.912.9131414.316.117.217.620.620.92121.221.825.627.132.534.936.937.240.241.141.642.944.944.745.846.245.845.745.8800000
------------------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The ABIOMED Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the ABIOMED is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (k)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (B)
198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022
                                                                       
2.413.310.424.621.818.49.53.14.510.69.326.418.2106.492.571.354.427.341.530.875.138.357.258.360.377.276.776.6132212.1229.9362.2491.7443.1583.7758.61
0.20.50.80.70.70.60.81.71.82.64.65.46.46.79.57.15.268.68.910.914.115.713.515.420.522.924.431.842.854.17090.884.797.290.61
000000000000000000000000000000000000
0.40.60.91.11.20.81.52.21.41.71.52.32.93.53.54.22.92.73.94.98.617.414.89.27.511.114.913.916.826.734.950.280.990.181.193.98
0.30.10.10.20.30.20.20.10.10.10.20.20.30.50.80.80.911.21.91.81.70.81.71.51.723.14.56.8811.813.7182633.28
3.314.512.226.62420127.17.81515.634.327.8117.1106.383.463.43755.246.596.471.588.582.784.7110.5116.5118185.1288.4326.9494.2677.1635.9788976.47
0.30.30.31.11.10.60.70.60.50.61.93.53.944.84.743.22.84.85.87.67.86.86.36.46.56.99.123.287.8117.2145176.7203.2212.01
000000006.50000000018.22.10003.700011.441.814147.150.1102.5302.2365.7351.94
0000000000000300200000000000000000000000
00000000000000.40.810.70.60.48.27.36.94.431.60.10014.715.414.516.715.222.647.545.64
000000000000000000019.126.731.631.337.238.936.835.43831.5333135.832.63278.676.79
00004.85.29.77.700.610.91.30.1000.40.30.5000.50.300000.884634372.381.847.111.410.55
0.30.30.31.15.95.810.48.371.22.94.45.24.85.85.75.122.35.832.139.846.647.54746.843.353.387.5153.3135.6223.4292.1377.1580.6706.4696.92
00.010.010.030.030.030.020.020.010.020.020.040.030.120.110.090.070.060.060.080.140.120.140.130.130.150.170.210.340.420.550.791.051.221.491.67
                                                                       
000100100100100100100100100100100200200200200200200300300300400400400400400400400400400400500500500455
2.914.614.631.733.133.233.333.436.536.637.257.558.2154.4162.3163.6164165.7170.1214.7292.5300.8362.1372.4379.2401.8414.8436.1465508.6566619.9690.5739.1800.7870.07
-0.6-1.1-3.4-5.3-11.9-17-20.9-22.9-23.2-22.8-22-24.5-31.2-41.7-62.8-83.9-102.1-111.5-113.9-143.3-171.2-212.4-244-263-274.8-273.3-258.3-250.9-137.2-99.1-47140.5399.5602.5828964.51
00000000000000000-0.1-0.3-2.10.65-1.7-10.7-1.8-3.7-0.7-17.3-14.5-20.6-4.2-14.7-11.2-11.4-27.16
000000000000000000000000000000000000
00.010.010.030.020.020.010.010.010.010.020.030.030.110.10.080.060.050.060.070.120.090.120.110.110.130.150.180.310.40.50.761.081.331.621.81
0.30.40.40.50.30.40.50.30.20.81.32.10.91.62.121.41.41.13.15.295.63.86.36.97.77.710.49.420.623.632.232.834.835.35
0.50.60.70.70.60.80.70.80.91.41.62.64.36.25.24.94.23.33.65.279.310.81313.311.513.116.520.425.934.541.645.257.162.673.59
0.60.10000000.30.10.30.30.50.24.42.40.90.20.10.50.71.21.21.32.746.36.28.511.313.719.528.74231.529.52
000000000000000000000000000000000000
00000000000002002001000000000000000080000000
1.41.11.11.20.91.21.21.11.42.33.255.78.211.99.46.54.94.88.812.919.517.618.122.322.427.130.439.346.669.684.7106.1131.9128.9138.46
00000000000000000000000000000015.500000
00000000000000000000.31.24.72.1344.85.66.40.80.80.80.90.80.80.80.78
000.107.88.38.73.80000.70.20.70.40000000.20.30.50.50.40.30.26.77.812.411.310.618.334.930.83
000.107.88.38.73.80000.70.20.70.400000.31.24.92.43.54.55.25.96.67.58.628.712.211.419.135.731.61
1.41.11.21.28.79.59.94.91.42.33.25.75.98.912.39.46.54.94.89.114.124.42021.626.827.6333746.855.298.396.9117.5151164.6170.07
00.010.010.030.030.030.020.020.010.020.020.040.030.120.110.090.070.060.060.080.140.120.140.130.130.150.190.220.360.450.60.851.191.481.781.98
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of ABIOMED provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand ABIOMED's financial health and stability.

Assets

ABIOMED's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that ABIOMED must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of ABIOMED after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into ABIOMED's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
1986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022
000-2-1-6-5-3-2000-2-6-10-19-21-18-9-2-29-27-40-31-19-1111571133852112259203225136
000000000000011111113365434222361114202428
00000000000000000000000011000-87222542-733292
00000000-110-10-21-100-2-42-2-8-3-20-11-20-4-155-18-388-17-30
000003000000100700001461320131316202435575886809060201
0000000000000000000000000000000000000
000000000000000000000000000011014594861
000-2-1-3-3-4-30000-7-7-11-19-16-10-5-9-19-28-18-71326234376115192252314274285
0000-1000000-1-2-1-1-2-2-100-3-2-3-3-3-1-1-2-2-5-15-50-55-44-44-53-35
00-32-20500301-1-18133-1-2514-291715-40-268-2-17-10-22-49-57-126-180-116-125-223-380
00-22-195003010-161441-2315-2821017-37-23120-15-7-19-44-42-75-124-72-81-170-345
0000000000000000000000000000000000000
0000000000000000000000000000000000000
0011017100000020096010142663461114-11101110121116-76316
0011017100000020096000142662461114-119973-9-55-117-8-2
-----------------------1.00-------2.00-3.00-8.00-20.00-71.00-41.00-11.00-18.00
0000000000000000000000000000000000000
0070-52-3-3002-11692-12-44-1-370061-670310311125-93787140-99
0.1-0.5-0.9-2.8-2.9-4.1-3.5-4.6-3.60.80.3-1.8-3.2-9-8.7-14.5-21.7-17.2-10.5-5.9-12.4-22.2-32.7-22.1-11-0.21.923.620.738.161.264.7136.6208.2270.9221.2249.63
0000000000000000000000000000000000000

ABIOMED stock margins

The ABIOMED margin analysis displays the gross margin, EBIT margin, as well as the profit margin of ABIOMED. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for ABIOMED.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the ABIOMED's sales revenue. A higher gross margin percentage indicates that the ABIOMED retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the ABIOMED's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the ABIOMED's total revenue generated. When comparing the revenue margin year over year, investors can gauge the ABIOMED's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the ABIOMED. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the ABIOMED's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

ABIOMED Margin History

ABIOMED Gross marginABIOMED Profit marginABIOMED EBIT marginABIOMED Profit margin
2027e0 %0 %0 %
2026e0 %0 %0 %
2025e0 %0 %0 %
2024e0 %0 %0 %
2023e0 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %
20140 %0 %0 %
20130 %0 %0 %
20120 %0 %0 %
20110 %0 %0 %
20100 %0 %0 %
20090 %0 %0 %
20080 %0 %0 %
20070 %0 %0 %
20060 %0 %0 %
20050 %0 %0 %
20040 %0 %0 %
20030 %0 %0 %

ABIOMED Stock Sales Revenue, EBIT, Earnings per Share

The ABIOMED earnings per share therefore indicates how much revenue ABIOMED has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue ABIOMED earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates ABIOMED's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of ABIOMED’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating ABIOMED's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

ABIOMED Revenue, EBIT and net profit per share

DateABIOMED Sales per ShareABIOMED EBIT per shareABIOMED Earnings per Share
2027e0 undefined0 undefined0 undefined
2026e0 undefined0 undefined0 undefined
2025e0 undefined0 undefined0 undefined
2024e0 undefined0 undefined0 undefined
2023e0 undefined0 undefined0 undefined
20220 undefined0 undefined0 undefined
20210 undefined0 undefined0 undefined
20200 undefined0 undefined0 undefined
20190 undefined0 undefined0 undefined
20180 undefined0 undefined0 undefined
20170 undefined0 undefined0 undefined
20160 undefined0 undefined0 undefined
20150 undefined0 undefined0 undefined
20140 undefined0 undefined0 undefined
20130 undefined0 undefined0 undefined
20120 undefined0 undefined0 undefined
20110 undefined0 undefined0 undefined
20100 undefined0 undefined0 undefined
20090 undefined0 undefined0 undefined
20080 undefined0 undefined0 undefined
20070 undefined0 undefined0 undefined
20060 undefined0 undefined0 undefined
20050 undefined0 undefined0 undefined
20040 undefined0 undefined0 undefined
20030 undefined0 undefined0 undefined

ABIOMED business model

Abiomed Inc. is one of the most innovative companies in the medical technology industry. It was founded in 1981 and is headquartered in Danvers, Massachusetts. The company specializes in the development, manufacturing, and marketing of medical devices aimed at saving or improving patients' lives. Abiomed started as a small company focused on implantation technology for cardiac arrhythmias. However, the company soon recognized the need to concentrate on providing solutions for cardiac intensive care. Today, Abiomed is a leader in the field of cardiopulmonary support systems and offers innovative devices to support the heart. Abiomed's business model revolves around leveraging its expertise in medical technology for cardiology interventions and intensive care and bringing innovative products to market. The company has industry experts and doctors on its team who contribute to the development and manufacturing of products. This highest level of professionalism is also reflected in the distribution channels Abiomed utilizes, with a focus on delivering its products to clinics specialized in critical medical interventions. Abiomed is divided into various business segments that concentrate on the medical devices the company offers. One of these segments is the Impella portfolio, which focuses on heart pumps for acute heart failure. These pumps are capable of supporting the heart during cardiological intervention by pumping blood into the heart while artificially ventilating it. The Impella portfolio is recognized as a standard in cardiac intensive care. Another important area for Abiomed is product development. The company heavily invests in researching and developing new products to meet the current demand in cardiology on the market. Abiomed is aware that rapid development of new products can provide a competitive advantage and, therefore, is an essential part of its business model. The technology offered by Abiomed is revolutionary and allows for the treatment of patients with acute heart failure, which was previously difficult or impossible. This is a significant milestone for the company and the healthcare industry in general. Abiomed is aware of its responsibility towards patients, doctors, and hospitals and is continuously working to develop innovative solutions for the healthcare industry. In summary, Abiomed Inc. is a leading company in the medical technology industry that focuses on cardiology intervention and intensive care. The company is innovative and offers products that can save and improve patients' lives. The Impella portfolio, specializing in acute heart failure, is an important part of its business model. Abiomed heavily invests in research and development to consistently provide innovative solutions to its customers. ABIOMED is one of the most popular companies on Eulerpool.com.

ABIOMED SWOT Analysis

Strengths

ABIOMED Inc possesses several key strengths that contribute to its success in the market. These strengths include:

ABIOMED is renowned for its cutting-edge medical technology and devices. The company continuously invests in research and development, allowing it to create innovative products that address critical healthcare challenges.

ABIOMED holds a prominent position in the medical device industry due to its extensive product portfolio and global market presence. The company's strong brand recognition and customer loyalty contribute to its market dominance.

ABIOMED has consistently demonstrated robust financial performance, generating high revenue growth and profitability. Its strong financial position enables the company to invest in future growth opportunities and withstand market fluctuations.

Weaknesses

Despite its overall success, ABIOMED Inc also faces certain weaknesses that may impact its performance. These weaknesses include:

ABIOMED's product portfolio is primarily focused on cardiovascular devices. This narrow product range increases the company's vulnerability to changes in market demand and intensifies competition.

The medical device industry is heavily regulated, and ABIOMED must ensure compliance with various regulatory bodies. Delays or issues in obtaining necessary approvals can hinder product launches and expansion into new markets.

As a leading medical device company, ABIOMED is exposed to the risk of litigation related to product safety or liability claims. Legal disputes can be time-consuming, expensive, and damage the company's reputation.

Opportunities

ABIOMED Inc can capitalize on several key opportunities to enhance its business prospects. These opportunities include:

The global healthcare market is expanding rapidly, driven by an aging population and increased prevalence of cardiovascular diseases. ABIOMED can leverage this growth by introducing its innovative products in emerging markets.

Rapid advancements in medical technology present opportunities for ABIOMED to develop and market new products. By staying at the forefront of technological innovations, the company can meet evolving customer needs and gain a competitive edge.

Collaborating with other healthcare organizations, research institutions, or strategic partners can provide ABIOMED with access to complementary expertise and resources. Strategic partnerships can accelerate product development, market entry, and improve market reach.

Threats

ABIOMED Inc must be aware of potential threats that could hinder its growth and market position. These threats include:

The medical device industry is highly competitive, with numerous established players and new entrants vying for market share. ABIOMED faces the risk of competitors introducing similar or superior products, leading to pricing pressures and erosion of market share.

Global economic fluctuations and uncertainties can impact healthcare spending and buying patterns. A decrease in healthcare budgets or changes in reimbursement policies may directly affect ABIOMED's sales and profitability.

Regulatory bodies frequently update and modify regulations for medical devices. ABIOMED must remain vigilant in complying with these changing regulations and investing in ongoing quality assurance and regulatory compliance activities.

ABIOMED Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

ABIOMED Revenue by Segment

Segmente2022202120202019
Impella product-806.32 M USD806.82 M USD741.7 M USD
Product984.54 M USD---
Service and other47.21 M USD41.2 M USD34.06 M USD27.73 M USD

ABIOMED Revenue by Region

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

ABIOMED Revenue by Segment

DateEuropeInternationalJapanJAPANOther internationalOutside the U.S MemberRest of worldU.SUnited States
2022131.91 M USD--51.69 M USD-194.14 M USD10.54 M USD-837.61 M USD
2021105.32 M USD-42.87 M USD-7.76 M USD---691.58 M USD
2020-135.47 M USD-----705.41 M USD-
2019-104.35 M USD-----665.08 M USD-

ABIOMED Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

ABIOMED historical P/E ratio, EBIT, and P/S ratio.

ABIOMED shares outstanding

The number of shares was ABIOMED in 2023 — This indicates how many shares 45.881 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue ABIOMED earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates ABIOMED's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of ABIOMED’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating ABIOMED's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

ABIOMED Stock splits

In ABIOMED's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for ABIOMED.

ABIOMED latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/20220 0  (22.72 %)2023 Q2
6/30/20220 0  (16.08 %)2023 Q1
3/31/20220 0  (4.67 %)2022 Q4
12/31/20210 0  (16.62 %)2022 Q3
9/30/20210 0  (3.81 %)2022 Q2
6/30/20210 0  (31.11 %)2022 Q1
3/31/20210 0  (10.9 %)2021 Q4
12/31/20200 0  (17.28 %)2021 Q3
9/30/20200 0  (44.74 %)2021 Q2
6/30/20200 0  (226.88 %)2021 Q1
1
2
3
4
5
...
10

ABIOMED list of shareholders

%
Name
Stocks
Change
Date
8.03912 % Baillie Gifford & Co.3,624,937-84,8849/30/2022
5.86105 % BlackRock Institutional Trust Company, N.A.2,642,8162,7229/30/2022
4.59331 % State Street Global Advisors (US)2,071,180-15,5909/30/2022
3.34050 % PRIMECAP Management Company1,506,272-32,9809/30/2022
3.22384 % Wellington Management Company, LLP1,453,669263,4129/30/2022
2.96885 % Generation Investment Management LLP1,338,692-7,0229/30/2022
2.80720 % Renaissance Technologies LLC1,265,800-180,7239/30/2022
2.79537 % Brown Capital Management, LLC1,260,466-1,9939/30/2022
2.77628 % Winslow Capital Management, LLC1,251,859-25,7349/30/2022
2.66888 % AllianceBernstein L.P.1,203,43122,6899/30/2022
1
2
3
4
5
...
10

ABIOMED Executives and Management Board

Mr. Michael Minogue55
ABIOMED Chairman of the Board, President, Chief Executive Officer (since 2004)
Compensation 12.67 M
Mr. Todd Trapp51
ABIOMED Chief Financial Officer, Executive Vice President
Compensation 3.04 M
Mr. Andrew Greenfield49
ABIOMED Executive Vice President, Chief Commercial Officer
Compensation 2.84 M
Mr. Marc Began55
ABIOMED Executive Vice President, General Counsel, Company Secretary
Compensation 2.57 M
Dr. Paula Johnson62
ABIOMED Independent Director
Compensation 499,891
1
2
3

ABIOMED Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Opsens Inc. Stock
Opsens Inc.
SupplierCustomer0,590,430,160,590,63-
Kaman Corporation Stock
Kaman Corporation
SupplierCustomer0,270,690,590,24-0,44-0,12
Opsens Stock
Opsens
SupplierCustomer0,160,260,100,580,610,72
1

Most common questions regarding ABIOMED

What values and corporate philosophy does ABIOMED represent?

ABIOMED Inc represents the values of innovation, excellence, and patient-centered care. The company's corporate philosophy focuses on developing advanced medical technologies to improve patient outcomes and transform healthcare. ABIOMED is committed to providing innovative solutions for heart recovery and support, such as their flagship product, the Impella heart pump system. With a dedication to clinical and economic value, ABIOMED prioritizes patient safety and quality, while driving growth and delivering shareholder value. Through continuous research, development, and collaboration, ABIOMED aims to redefine the standard of care for patients suffering from advanced heart failure.

In which countries and regions is ABIOMED primarily present?

ABIOMED Inc is primarily present in the United States.

What significant milestones has the company ABIOMED achieved?

ABIOMED Inc, a leading medical technology company specializing in mechanical circulatory support devices, has achieved several significant milestones. The company's flagship product, the Impella heart pump, has obtained multiple regulatory approvals, including the FDA's Pre-Market Approval (PMA). ABIOMED has successfully expanded its global footprint and established a presence in Europe, Asia, and Latin America. The company has experienced exponential growth, surpassing $800 million in annual revenue. ABIOMED's commitment to innovation is demonstrated by the introduction of the world's smallest heart pump, Impella 2.5, and the Impella CP, both revolutionizing cardiac care. Through its relentless pursuit of improving patient outcomes, ABIOMED continues to play a pivotal role in advancing heart recovery and transforming the field of cardiovascular medicine.

What is the history and background of the company ABIOMED?

ABIOMED Inc is a renowned medical technology company specializing in innovative heart pump devices. Founded in 1981, ABIOMED has a rich history of revolutionizing the field of mechanical circulatory support. With its flagship product, the FDA-approved Impella heart pumps, ABIOMED has transformed the treatment of patients suffering from heart failure worldwide. The company's cutting-edge technologies have significantly improved patient outcomes and survival rates. With a strong commitment to research and development, ABIOMED continues to lead the way in creating advanced solutions for cardiac care. ABIOMED Inc's dedication to excellence and patient-centric approach have made it a trusted name in the medical industry.

Who are the main competitors of ABIOMED in the market?

The main competitors of ABIOMED Inc in the market include Medtronic, Inc., Edwards Lifesciences Corporation, and Boston Scientific Corporation.

In which industries is ABIOMED primarily active?

ABIOMED Inc is primarily active in the medical devices industry.

What is the business model of ABIOMED?

The business model of ABIOMED Inc is focused on the development, production, and marketing of medical devices designed to support or replace the failing heart. ABIOMED specializes in advanced heart recovery, offering a range of products to address various cardiovascular conditions. Their flagship product, the Impella heart pump, provides temporary circulatory support to patients undergoing high-risk procedures such as percutaneous coronary intervention (PCI) and helps maintain stable hemodynamics. By consistently introducing innovative solutions for heart recovery, ABIOMED aims to improve patient outcomes and enhance the standard of care in cardiology.

What is the P/E ratio of ABIOMED 2024?

The P/E ratio cannot be calculated for ABIOMED at the moment.

What is the P/S ratio of ABIOMED 2024?

The P/S cannot be calculated for ABIOMED currently.

What is the AlleAktien quality score of ABIOMED?

The AlleAktien quality score for ABIOMED is 8/10.

What is the revenue of ABIOMED 2024?

The revenue cannot currently be calculated for ABIOMED.

How high is the profit of ABIOMED 2024?

The profit cannot currently be calculated for ABIOMED.

What is the business model of ABIOMED

ABIOMED Inc. is a leading company in the development, manufacturing, and marketing of medical devices for heart care. Founded in 1981 in Danvers, Massachusetts, ABIOMED specializes in the development of advanced technologies for the treatment of heart failure. They employ continuous improvement and innovation to enhance the lives of patients worldwide. The company is divided into various divisions, including research and development, marketing and sales, and manufacturing and production of products. Research and development constantly develop and improve new technologies to meet the needs of patients and market demands. Marketing and sales ensure the global sale and promotion of devices, while manufacturing and production ensure that all the company's products meet high quality standards. ABIOMED offers a range of products for heart care, with their flagship product being the Impella. Impella is a miniature pumping system used for short-term support of heart function in patients with severe heart disease. Impella works by continuously removing blood from the left ventricle of the heart and directly pumping it into the aorta. This improves heart function and ensures adequate blood supply to vital organs. The system is very small and is inserted into the heart during a minimally invasive procedure, reducing patient recovery time. In addition to the flagship product, ABIOMED also offers other devices for heart care, including the high-performance implant ECMO (extracorporeal membrane oxygenation), used for body support during heart surgery or severe lung problems. There are also other products, including heart monitors and probes used for monitoring, diagnosing, and treating patients with heart disease. ABIOMED's business model is focused on meeting the needs of patients, hospitals, and healthcare organizations worldwide. It is a research and innovation-based company that utilizes the latest developments in technology to improve patient care. Through extensive research programs and close collaboration with physicians and healthcare professionals, ABIOMED is able to find innovative solutions to complex medical problems. Additionally, the company has a strong global presence, allowing it to distribute its products internationally. In 2019, the company generated $769.4 million in revenue and had over 1,600 employees worldwide. Overall, ABIOMED offers innovative and advanced technologies for heart care that can improve the lives of patients worldwide. With a high-quality business model, strong global presence, and constant innovation, the company remains ready to meet the challenges and demands of the healthcare industry.

What is the ABIOMED dividend?

ABIOMED pays a dividend of 0 USD distributed over payouts per year.

How often does ABIOMED pay dividends?

The dividend cannot currently be calculated for ABIOMED or the company does not pay out a dividend.

What is the ABIOMED ISIN?

The ISIN of ABIOMED is US0036541003.

What is the ABIOMED WKN?

The WKN of ABIOMED is 873886.

What is the ABIOMED ticker?

The ticker of ABIOMED is ABMD.

How much dividend does ABIOMED pay?

Over the past 12 months, ABIOMED paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ABIOMED is expected to pay a dividend of 0 USD.

What is the dividend yield of ABIOMED?

The current dividend yield of ABIOMED is .

When does ABIOMED pay dividends?

ABIOMED pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of ABIOMED?

ABIOMED paid dividends every year for the past 0 years.

What is the dividend of ABIOMED?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is ABIOMED located?

ABIOMED is assigned to the 'Health' sector.

Wann musste ich die Aktien von ABIOMED kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of ABIOMED from 9/27/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.

When did ABIOMED pay the last dividend?

The last dividend was paid out on 9/27/2024.

What was the dividend of ABIOMED in the year 2023?

In the year 2023, ABIOMED distributed 0 USD as dividends.

In which currency does ABIOMED pay out the dividend?

The dividends of ABIOMED are distributed in USD.

All fundamentals about ABIOMED

Our stock analysis for ABIOMED Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ABIOMED Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.